Search Results - subject:"Long-acting injectable"

Hospitalization rates and resource utilization of schizophrenic patients switched from oral antipsychotics to aripiprazole-depot in Germany

Potempa, Christoph; Rychlik, Reinhard - In: Health Economics Review 8 (2018) 30, pp. 1-11

Objective: Examine cost-driving factors of schizophrenia in Germany for patients prior- and post-switch from an oral antipsychotic therapy to aripiprazole-depot and perform a budget impact analysis (BIA) referring to the context of German health care. Methods: A single-armed, retrospective,...

Persistent link: https://www.econbiz.de/10012010786

Hospitalization rates and resource utilization of schizophrenic patients switched from oral antipsychotics to aripiprazole-depot in Germany

Potempa, Christoph; Rychlik, Reinhard - In: Health economics review 8 (2018) 30, pp. 1-11

Persistent link: https://www.econbiz.de/10011942937

Cost-effectiveness of long-acting injectable risperidone versus flupentixol decanoate in the treatment of schizophrenia: a Markov model parameterized using administrative data

Frey, Simon; Linder, Roland; Juckel, Georg; Stargardt, Tom - In: The European Journal of Health Economics 15 (2014) 2, pp. 133-142

-simulation model to assess the cost-effectiveness of long-acting injectable risperidone (LAI-RIS) compared with long-acting injectable …

Persistent link: https://www.econbiz.de/10010993904

Cost-effectiveness of long-acting injectable risperidone versus flupentixol decanoate in the treatment of schizophrenia : a Markov model parameterized using administrative data

Frey, Simon; Linder, Roland; Juckel, Georg; Stargardt, Tom - In: The European journal of health economics : HEPAC ; … 15 (2014) 2, pp. 133-142

Persistent link: https://www.econbiz.de/10010254965